Background
Patient privacy is a ubiquitous problem around the world. Many existing studies have demonstrated the potential privacy risks associated with sharing of biomedical data. Owing to the increasing need for data sharing and analysis, health care data privacy is drawing more attention. However, to better protect biomedical data privacy, it is essential to assess the privacy risk in the first place.
Objective
In China, there is no clear regulation for health systems to deidentify data. It is also not known whether a mechanism such as the Health Insurance Portability and Accountability Act (HIPAA) safe harbor policy will achieve sufficient protection. This study aimed to conduct a pilot study using patient data from Chinese hospitals to understand and quantify the privacy risks of Chinese patients.
Methods
We used g-distinct analysis to evaluate the reidentification risks with regard to the HIPAA safe harbor approach when applied to Chinese patients’ data. More specifically, we estimated the risks based on the HIPAA safe harbor and limited dataset policies by assuming an attacker has background knowledge of the patient from the public domain.
Results
The experiments were conducted on 0.83 million patients (with data field of date of birth, gender, and surrogate ZIP codes generated based on home address) across 33 provincial-level administrative divisions in China. Under the Limited Dataset policy, 19.58% (163,262/833,235) of the population could be uniquely identifiable under the g-distinct metric (ie, 1-distinct). In contrast, the Safe Harbor policy is able to significantly reduce privacy risk, where only 0.072% (601/833,235) of individuals are uniquely identifiable, and the majority of the population is 3000 indistinguishable (ie the population is expected to share common attributes with 3000 or less people).
Conclusions
Through the experiments based on real-world patient data, this work illustrates that the results of g-distinct analysis about Chinese patient privacy risk are similar to those from a previous US study, in which data from different organizations/regions might be vulnerable to different reidentification risks under different policies. This work provides reference to Chinese health care entities for estimating patients’ privacy risk during data sharing, which laid the foundation of privacy risk study about Chinese patients’ data in the future.
Evaluation of Privacy Risks of Patients’ Data in China: Case Study
